What Triggers Scleroderma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 30, 2020 Category: General Medicine Source Type: news
CHMP_opinion_nintedanib_ILD_PF
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in mo...
Source: Boehringer Ingelheim Corporate News - May 29, 2020 Category: Research Source Type: news
Impact of organ involvement on healthcare utilisation for systemic sclerosis in England
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2020 Category: Drugs & Pharmacology Source Type: news
European_Commission_approves_nintedanibSSc-ILD
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need (Source: Boehringer Inge...
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news
I ’ve Seen Wars and Epidemics Unfold. But Now That I Have an Immunocompromised Partner, the Coronavirus Makes Me Truly Scared
At midnight on Thursday March 26, all of South Africa went into lockdown. For the next 21 days, no one is to leave their homes unless they are going to the grocery store, the pharmacy or to seek medical help. No dog walking, no jogging, no food delivery services. Only essential workers are exempt, and that list is small. When President Cyril Ramaphosa made the announcement on March 23, a week after shutting the nation’s schools, there were only 402 confirmed COVID-19 cases. But it was essential, he said, to “flatten the curve” before widespread outbreaks overwhelmed the country’s fragile medical sys...
Source: TIME: Health - March 27, 2020 Category: Consumer Health News Authors: Aryn Baker Tags: Uncategorized COVID-19 feature Londontime Source Type: news
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the treatment ...
Source: Boehringer Ingelheim Corporate News - February 28, 2020 Category: Research Source Type: news
High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis
The first evidence-based consensus statements for systemic sclerosis-associated interstitial lung disease (SSc-ILD) recommend use of high-resolution computed tomography (CT) for screening and diagnosis, and offer guidance on when to initiate or escalate emerging treatment options.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 4, 2020 Category: Radiology Tags: Rheumatology News Source Type: news
Hyaluronic Acid and Platelet-Rich Plasma for Scleroderma Hyaluronic Acid and Platelet-Rich Plasma for Scleroderma
Scleroderma patients treated with filler injections of hyaluronic acid and platelet-rich plasma realized improvements in skin atrophy and quality of life.Arthritis Research & Therapy (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2020 Category: Pathology Tags: Rheumatology Journal Article Source Type: news
Garmin's Kao donates $20M to create institute within hospital
Garmin Ltd. co-founder and Executive Chairman Min Kao has donated $20 million to a nonprofit Los Angeles hospital.
The gift from the Kao Family Foundation will create the Kao Autoimmunity Institute to advance research and treatment of rheumatologic diseases at Cedars-Sinai Medical Center, according to a Tuesday release.
The donation also will establish a program within the institute that provides training and education for people with scleroderma, a disease that causes chronic hardening and tightening… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 12, 2019 Category: Biotechnology Authors: Lily Lieberman Source Type: news
Researchers create accurate model of organ scarring using stem cells in a lab
Every organ in the body is capable, to some extent, of repairing itself after an injury. As part of this process, scar tissue forms and then recedes to make room for normal tissue when healing is complete.However, when healing is disrupted — whether by chronic injury or disease — the cells that make up scar tissue can go rogue, continuously dividing and spreading until the scar eventually strangles the organ it was intended to help heal, which can lead to organ failure.That progressive, out-of-control scarring is called fibrosis, and it can occur in any organ in the body. Fibrosis plays a major role in many diseases an...
Source: UCLA Newsroom: Health Sciences - December 11, 2019 Category: Universities & Medical Training Source Type: news
Systemic Sclerosis Highlights From 2019 ACR Annual Meeting Systemic Sclerosis Highlights From 2019 ACR Annual Meeting
Dr Robert Spiera of the Hospital for Special Surgery in New York City reviews key studies related to systemic sclerosis, presented at the 2019 American College of Rheumatology annual meeting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Rheumatology ReCAP Source Type: news
FDA Approves First Treatment for ILD With Systemic Sclerosis, Scleroderma
Title: FDA Approves First Treatment for ILD With Systemic Sclerosis, SclerodermaCategory: Health NewsCreated: 9/10/2019 12:00:00 AMLast Editorial Review: 9/10/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 10, 2019 Category: Rheumatology Source Type: news
FDA Approves First Treatment, Ofev (Nintedanib), for ILD With Systemic Sclerosis, Scleroderma
MONDAY, Sept. 9, 2019 -- The U.S. Food and Drug Administration granted the first approval for a drug to slow the decline of pulmonary function in interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD), the agency... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2019 Category: General Medicine Source Type: news
FDA OKs Nintedanib (Ofev) for Rare Lung Disease FDA OKs Nintedanib (Ofev) for Rare Lung Disease
Nintedanib capsules are approved for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease.News Alerts (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 9, 2019 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev ® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILDInterstitial lung disease (ILD) is the leading cause of death among people with systemic sclerosis (SSc) or scleroderma3 Approval is based on results from the Phase III SENSCIS ® study, the largest randomized controlled trial in SSc-ILD patientsRegulatory review of the additional indication in other countries is still ongoingOfev ® (nintedanib) is already approved in the U.S. and more than 70 countries for the treatment of idiopathic pulmonary fibrosis (IPF) ...
Source: Boehringer Ingelheim Corporate News - September 9, 2019 Category: Research Source Type: news
